Skip to main content

Table 1 Demographics and clinical characteristics of the study cohort (FACEHBI [29])

From: Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the FundaciĆ³ ACE Healthy Brain Initiative (FACEHBI)

Variable

SCD

Subjects, n

200

Age, years

65.87 (7.23)

Education, years

14.76 (4.73)

Gender, % males

37.5

APOE, % e4 allele carriers

26

Creatinine, mg/dl

0.92 (0.15)

Body mass index, kg/m2

26.64 (4.32)

Hematocrit, %

43.15 (4.93)

FBB-PET SUVR

1.2 (0.15)

FP42/40

0.04 (0.03)

TP42/40

0.09 (0.06)

FP40/TP40

0.44 (0.06)

BP42/40

0.13 (0.09)

FP42/TP42

0.24 (0.21)

  1. Data are shown as mean (SD) unless otherwise specified
  2. APOE apolipoprotein, BP bound peptide, FBB florbetaben(18F), FP free plasma, PET positron emission tomography, SCD subjective cognitive decline, SUVR standardized uptake value ratio, TP total plasma